Prevail Therapeutics Inc.

Operating margin

—

Net margin

—

Return on equity

−38.2%

Return on assets

−33.8%

Return on capital (ROCE)

−37.5%

Liabilities / assets

11.6%

Debt / equity

0.13×

Book value / share

$4.84

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

9.85safe

Accruals / assets

−4.0%clean

Piotroski F-Score

2/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Phase 1/2Active Not Recruitingreadout ~2028-05
  Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
• Phase 1Recruitingreadout ~2029-05-05
  A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
• Phase 1/2Active Not Recruitingreadout ~2029-11-30
  Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
• Phase 1/2Active Not Recruitingreadout ~2030-12-31
  Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
• Phase 1/2Recruitingreadout ~2032-08-30
  A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

• Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 22, 2021
• Entered a material agreement · Other material eventDec 15, 2020
• Results of operationsNov 13, 2020
• Regulation FD disclosureNov 12, 2020
• Regulation FD disclosureNov 2, 2020
• Director / officer change · Regulation FD disclosureSep 10, 2020
• Results of operations · Regulation FD disclosureAug 11, 2020
• Shareholder voteJun 17, 2020

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.